Literature DB >> 17987647

Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk.

Karen M Powers1, Denise M Kay, Stewart A Factor, Cyrus P Zabetian, Donald S Higgins, Ali Samii, John G Nutt, Alida Griffith, Berta Leis, John W Roberts, Erica D Martinez, Jennifer S Montimurro, Harvey Checkoway, Haydeh Payami.   

Abstract

Inverse associations of Parkinson's disease (PD) with cigarette smoking, coffee drinking, and nonsteroidal anti-inflammatory drug (NSAID) use have been reported individually, but their joint effects have not been examined. To quantify associations with PD for the individual, two-way and three-way combinations of these factors, a case-control association study with 1,186 PD patients and 928 controls was conducted. The study setting was the NeuroGenetics Research Consortium. Subjects completed a structured questionnaire regarding smoking, coffee, and NSAID consumption. Odds ratios were calculated using unconditional logistic regression. Smoking, coffee, and over the counter NSAID use as individual factors exhibited significantly reduced risks of 20% to 30%. The two-way and three-way combinations were associated with risk reduction of 37% to 49%, and 62%, respectively. Smoking and coffee exhibited significant inverse risk trends with increasing cumulative exposures, suggesting dose-response relations. With respect to the combination of all three exposures, persons who were at the highest exposure strata for smoking and coffee and used NSAIDs had an estimated 87% reduction in risk (OR = 0.13, 95% CI = 0.06-0.29). Whether this finding reflects true biologic protection needs to be investigated. 2007 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17987647     DOI: 10.1002/mds.21782

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  56 in total

Review 1.  Missing pieces in the Parkinson's disease puzzle.

Authors:  Jose A Obeso; Maria C Rodriguez-Oroz; Christopher G Goetz; Concepcion Marin; Jeffrey H Kordower; Manuel Rodriguez; Etienne C Hirsch; Matthew Farrer; Anthony H V Schapira; Glenda Halliday
Journal:  Nat Med       Date:  2010-05-23       Impact factor: 53.440

Review 2.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  An attempt to replicate interaction between coffee and CYP1A2 gene in connection to Parkinson's disease.

Authors:  E M Hill-Burns; T H Hamza; C P Zabetian; S A Factor; H Payami
Journal:  Eur J Neurol       Date:  2011-09       Impact factor: 6.089

4.  A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2.

Authors:  D M Kay; C F Stevens; T H Hamza; J S Montimurro; C P Zabetian; S A Factor; A Samii; A Griffith; J W Roberts; E S Molho; D S Higgins; S Gancher; L Moses; S Zareparsi; P Poorkaj; T Bird; J Nutt; G D Schellenberg; H Payami
Journal:  Neurology       Date:  2010-09-28       Impact factor: 9.910

5.  Exploring gene-environment interactions in Parkinson's disease.

Authors:  Colin C McCulloch; Denise M Kay; Stewart A Factor; Ali Samii; John G Nutt; Donald S Higgins; Alida Griffith; John W Roberts; Berta C Leis; Jennifer S Montimurro; Cyrus P Zabetian; Haydeh Payami
Journal:  Hum Genet       Date:  2008-01-22       Impact factor: 4.132

Review 6.  Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

Authors:  Marie Therese Armentero; Annalisa Pinna; Sergi Ferré; José Luis Lanciego; Christa E Müller; Rafael Franco
Journal:  Pharmacol Ther       Date:  2011-07-23       Impact factor: 12.310

7.  Partial linear varying multi-index coefficient model for integrative gene-environment interactions.

Authors:  Xu Liu; Yuehua Cui; Runze Li
Journal:  Stat Sin       Date:  2016-07       Impact factor: 1.261

Review 8.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

9.  Autoimmune disease and risk for Parkinson disease: a population-based case-control study.

Authors:  K Rugbjerg; S Friis; B Ritz; E S Schernhammer; L Korbo; J H Olsen
Journal:  Neurology       Date:  2009-09-23       Impact factor: 9.910

Review 10.  Adenosine receptors as drug targets--what are the challenges?

Authors:  Jiang-Fan Chen; Holger K Eltzschig; Bertil B Fredholm
Journal:  Nat Rev Drug Discov       Date:  2013-04       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.